Literature DB >> 31123922

Treatment Strategies in ANCA-Associated Vasculitis.

Nkechinyere Emejuaiwe1.   

Abstract

PURPOSE OF REVIEW: The long-term survival of patients with antineutrophil cytoplasmic antibody-associated vasculitis (AAV) has improved dramatically as a direct result of evolving therapy. This review summarizes evidence-based treatment strategies with currently approved immunosuppressive medications to serve as a guide for practitioners in the management of patients with AAV. RECENT
FINDINGS: Targeted therapy aimed at minimizing treatment-related adverse effects while optimizing effectiveness is a propagated approach. Such tailored therapy considers disease severity and is especially warranted in those at high risk for relapsing vasculitis. As treatment options for AAV become available, the need to tailor therapy has become increasingly relevant to optimize patient outcomes.

Entities:  

Keywords:  Antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis; Cyclophosphamide; Mycophenolate mofetil; Plasma exchange; Remission induction, remission maintenance; Rituximab

Year:  2019        PMID: 31123922     DOI: 10.1007/s11926-019-0835-8

Source DB:  PubMed          Journal:  Curr Rheumatol Rep        ISSN: 1523-3774            Impact factor:   4.592


  23 in total

1.  Effects of duration of glucocorticoid therapy on relapse rate in antineutrophil cytoplasmic antibody-associated vasculitis: A meta-analysis.

Authors:  Michael Walsh; Peter A Merkel; Alfred Mahr; David Jayne
Journal:  Arthritis Care Res (Hoboken)       Date:  2010-08       Impact factor: 4.794

2.  Rituximab versus cyclophosphamide for ANCA-associated vasculitis.

Authors:  John H Stone; Peter A Merkel; Robert Spiera; Philip Seo; Carol A Langford; Gary S Hoffman; Cees G M Kallenberg; E William St Clair; Anthony Turkiewicz; Nadia K Tchao; Lisa Webber; Linna Ding; Lourdes P Sejismundo; Kathleen Mieras; David Weitzenkamp; David Ikle; Vicki Seyfert-Margolis; Mark Mueller; Paul Brunetta; Nancy B Allen; Fernando C Fervenza; Duvuru Geetha; Karina A Keogh; Eugene Y Kissin; Paul A Monach; Tobias Peikert; Coen Stegeman; Steven R Ytterberg; Ulrich Specks
Journal:  N Engl J Med       Date:  2010-07-15       Impact factor: 91.245

3.  Rituximab versus cyclophosphamide in ANCA-associated renal vasculitis.

Authors:  Rachel B Jones; Jan Willem Cohen Tervaert; Thomas Hauser; Raashid Luqmani; Matthew D Morgan; Chen Au Peh; Caroline O Savage; Mårten Segelmark; Vladimir Tesar; Pieter van Paassen; Dorothy Walsh; Michael Walsh; Kerstin Westman; David R W Jayne
Journal:  N Engl J Med       Date:  2010-07-15       Impact factor: 91.245

Review 4.  Epidemiology of systemic vasculitis.

Authors:  Suzanne E Lane; Richard Watts; David G I Scott
Journal:  Curr Rheumatol Rep       Date:  2005-08       Impact factor: 4.592

5.  Rituximab for refractory granulomatosis with polyangiitis (Wegener's granulomatosis): comparison of efficacy in granulomatous versus vasculitic manifestations.

Authors:  Julia U Holle; Christin Dubrau; Karen Herlyn; Martin Heller; Petra Ambrosch; Bernhard Noelle; Eva Reinhold-Keller; Wolfgang L Gross
Journal:  Ann Rheum Dis       Date:  2011-10-21       Impact factor: 19.103

6.  Mycophenolate mofetil vs azathioprine for remission maintenance in antineutrophil cytoplasmic antibody-associated vasculitis: a randomized controlled trial.

Authors:  Thomas F Hiemstra; Michael Walsh; Alfred Mahr; Caroline O Savage; Kirsten de Groot; Lorraine Harper; Thomas Hauser; Irmgard Neumann; Vladimir Tesar; Karl-Martin Wissing; Christian Pagnoux; Wilhelm Schmitt; David R W Jayne
Journal:  JAMA       Date:  2010-11-08       Impact factor: 56.272

Review 7.  Outcomes from studies of antineutrophil cytoplasm antibody associated vasculitis: a systematic review by the European League Against Rheumatism systemic vasculitis task force.

Authors:  C Mukhtyar; O Flossmann; B Hellmich; P Bacon; M Cid; J W Cohen-Tervaert; W L Gross; L Guillevin; D Jayne; A Mahr; P A Merkel; H Raspe; D Scott; J Witter; H Yazici; R A Luqmani
Journal:  Ann Rheum Dis       Date:  2007-10-02       Impact factor: 19.103

8.  Azathioprine or methotrexate maintenance for ANCA-associated vasculitis.

Authors:  Christian Pagnoux; Alfred Mahr; Mohamed A Hamidou; Jean-Jacques Boffa; Marc Ruivard; Jean-Pierre Ducroix; Xavier Kyndt; François Lifermann; Thomas Papo; Marc Lambert; José Le Noach; Mehdi Khellaf; Dominique Merrien; Xavier Puéchal; Stéphane Vinzio; Pascal Cohen; Luc Mouthon; Jean-François Cordier; Loïc Guillevin
Journal:  N Engl J Med       Date:  2008-12-25       Impact factor: 91.245

9.  Wegener granulomatosis: an analysis of 158 patients.

Authors:  G S Hoffman; G S Kerr; R Y Leavitt; C W Hallahan; R S Lebovics; W D Travis; M Rottem; A S Fauci
Journal:  Ann Intern Med       Date:  1992-03-15       Impact factor: 25.391

10.  Randomized trial of plasma exchange or high-dosage methylprednisolone as adjunctive therapy for severe renal vasculitis.

Authors:  David R W Jayne; Gill Gaskin; Niels Rasmussen; Daniel Abramowicz; Franco Ferrario; Loic Guillevin; Eduardo Mirapeix; Caroline O S Savage; Renato A Sinico; Coen A Stegeman; Kerstin W Westman; Fokko J van der Woude; Robert A F de Lind van Wijngaarden; Charles D Pusey
Journal:  J Am Soc Nephrol       Date:  2007-06-20       Impact factor: 10.121

View more
  6 in total

1.  Clinical characteristics of patients with vasculitis positive for anti-neutrophil cytoplasmic antibody targeting both proteinase 3 and myeloperoxidase: a retrospective study.

Authors:  Sun Moon Kim; Song-Yi Choi; Seon Young Kim; Jinhyun Kim
Journal:  Rheumatol Int       Date:  2019-09-24       Impact factor: 2.631

Review 2.  Eosinophilic Vasculitis.

Authors:  Karen L Vega Villanueva; Luis R Espinoza
Journal:  Curr Rheumatol Rep       Date:  2020-01-11       Impact factor: 4.592

3.  Healthcare and economic burden of ANCA-associated vasculitis in Italy: an integrated analysis from clinical and administrative databases.

Authors:  Luca Quartuccio; Elena Treppo; Francesca Valent; Salvatore De Vita
Journal:  Intern Emerg Med       Date:  2020-07-14       Impact factor: 3.397

4.  Predictive factors of mortality in granulomatosis with polyangiitis: A single-center study.

Authors:  Müge Aydın Tufan; Nihan Tekkarışmaz
Journal:  Arch Rheumatol       Date:  2021-02-08       Impact factor: 1.472

Review 5.  Frailty in Rheumatic Diseases.

Authors:  Francesca Motta; Antonio Sica; Carlo Selmi
Journal:  Front Immunol       Date:  2020-10-29       Impact factor: 7.561

6.  Factors affecting relapse in patients with Granulomatosis Polyangiitis: a single-center retrospective cohort study

Authors:  Müge Aydın Tufan; Nihan Tekkarışmaz; Ahmet Eftal Yücel
Journal:  Turk J Med Sci       Date:  2021-08-30       Impact factor: 0.973

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.